{"id":249108,"date":"2026-09-16T12:14:36","date_gmt":"2026-09-16T06:44:36","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=249108"},"modified":"2026-09-16T12:14:36","modified_gmt":"2026-09-16T06:44:36","slug":"indoco-remedies-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Indoco Remedies Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Indoco Remedies share price Rs 238.10 on 16 September 2026, down 1.36%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 65.00 crore. Q2 FY26 base a loss of Rs 9.00 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Indoco Remedies Q2 results date for FY27 is not confirmed, and Indoco Remedies Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 485.00 crore in revenue and a loss of Rs 9.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Indoco Remedies Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/indoco\/indoco-remedies-ltd-share-price-today\">Indoco Remedies Ltd.<\/a>, Indoco Remedies Ltd. manufactures and markets generic and branded pharmaceutical formulations for domestic and international markets.. The stock traded at Rs 238.10 on the NSE on 16 September 2026, down 1.36% from the previous close of Rs 241.39, about 26.7% below its 52-week high of Rs 325.00 and 46.8% above its 52-week low of Rs 162.19.<\/p>\n<p>What makes the Indoco Remedies Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 485.00 crore of revenue and a loss of Rs 9.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 468.00 crore and a profit of Rs 65.00 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=indoco_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#When_Is_the_Indoco_Remedies_Q2_Results_FY27_Date\" title=\"When Is the Indoco Remedies Q2 Results FY27 Date?\">When Is the Indoco Remedies Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Indoco_Remedies_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Indoco Remedies Q2 Results Expectations: What the Market Is Actually Tracking\">Indoco Remedies Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Indoco_Remedies_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Indoco Remedies Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Indoco Remedies Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Indoco_Remedies_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Indoco Remedies Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Indoco Remedies Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Indoco_Remedies_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Indoco Remedies Quarterly Results Trend Over the Last Four Quarters\">Indoco Remedies Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Indoco_Remedies_Q2_Results_FY27\" title=\"Key Factors That Could Shape Indoco Remedies Q2 Results FY27\">Key Factors That Could Shape Indoco Remedies Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Valuation_Snapshot\" title=\"Valuation Snapshot\">Valuation Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Technical_and_Price_Context\" title=\"Technical and Price Context\">Technical and Price Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Balance_Sheet_and_Payout\" title=\"Balance Sheet and Payout\">Balance Sheet and Payout<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Indoco_Remedies_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Indoco Remedies Q2 Results FY27: Share Price and Valuation Going Into the Print\">Indoco Remedies Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Indoco_Remedies_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Indoco Remedies Q2 Results Are Announced\">What Investors Should Watch When Indoco Remedies Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Indoco_Remedies_Q2_Results_FY27\" title=\"Conclusion on Indoco Remedies Q2 Results FY27\">Conclusion on Indoco Remedies Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#FAQs_on_Indoco_Remedies_Q2_Results_FY27\" title=\"FAQs on Indoco Remedies Q2 Results FY27\">FAQs on Indoco Remedies Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#What_is_the_Indoco_Remedies_Q2_results_date_for_FY27\" title=\"What is the Indoco Remedies Q2 results date for FY27?\">What is the Indoco Remedies Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Indoco_Remedies_Q2_results_2026_cover\" title=\"What quarter do the Indoco Remedies Q2 results 2026 cover?\">What quarter do the Indoco Remedies Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#What_were_the_Indoco_Remedies_Q1_FY27_results\" title=\"What were the Indoco Remedies Q1 FY27 results?\">What were the Indoco Remedies Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#What_were_Indoco_Remedies_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Indoco Remedies Q2 FY26 results in the September 2025 quarter?\">What were Indoco Remedies Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Indoco_Remedies_Q2_results_expectations_this_quarter\" title=\"What are the main Indoco Remedies Q2 results expectations this quarter?\">What are the main Indoco Remedies Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#What_is_Indoco_Remedies_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Indoco Remedies share price today ahead of the Q2 earnings?\">What is Indoco Remedies share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q2-results-fy27-preview-date-expectations\/#Is_Indoco_Remedies_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Indoco Remedies a good stock to buy before the Q2 results?\">Is Indoco Remedies a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Indoco_Remedies_Q2_Results_FY27_Date\"><\/span><strong>When Is the Indoco Remedies Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Indoco Remedies Q2 results date for FY27 is not confirmed. As of 16 September 2026, Indoco Remedies Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Indoco Remedies Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/gujarat-fluorochemicals-q2-results-fy27-preview-date-expectations\">Gujarat Fluorochemicals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter<\/a><\/p>\n<p>The Indoco Remedies Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Indoco Remedies.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Indoco Remedies Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Indoco Remedies Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Indoco Remedies. The Indoco Remedies Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>Indoco Remedies Q2 results are being watched against a five-quarter revenue path that has stayed relatively steady even as profitability struggled. Revenue was Rs 440 crore in Jun25, rose to Rs 485 crore in Sep25, eased to Rs 445 crore in Dec25, rose again to Rs 476 crore in Mar26, and stood at Rs 468 crore in Jun26. This revenue range of roughly Rs 440 crore to Rs 485 crore has held fairly narrow even while the company&#8217;s bottom line moved through a difficult stretch. Those following Indoco Remedies Q2 results for the September 2026 quarter will likely focus more on the profit line than on revenue, given what happened below the operating level in recent quarters. The Indoco Remedies Q2 results series illustrates a business where the top line has been more stable than earnings.<\/p>\n<p>Operating margin at Indoco Remedies improved unevenly across the five quarters: 4.0% in Jun25, 9% in Sep25, 7% in Dec25, 10% in Mar26, and 9% in Jun26. Net profit tells a starker story. Indoco Remedies reported net losses in four consecutive quarters: Rs 36 crore lost in Jun25, Rs 9 crore lost in Sep25, Rs 29 crore lost in Dec25, and Rs 24 crore lost in Mar26, before swinging to a net profit of Rs 65 crore in Jun26. That Jun26 profit figure is larger than the quarter&#8217;s own operating profit of Rs 41 crore, which points to a material non-operating item, such as a one-off gain, forex movement, or tax credit, behind the swing rather than a clean operational turnaround. That distinction matters for how Indoco Remedies Q2 results are interpreted this cycle, and Indoco Remedies Q2 results should be described plainly as four straight quarters of losses followed by a profit boosted by items below the operating line, not as confirmation of a turnaround.<\/p>\n<p>On valuation, standard P\/E and EPS figures are not meaningful for Indoco Remedies given the trailing loss position across most of the review period, so these ratios should not be treated as a valuation signal right now. Book value is Rs 102 per share, and against the current price the stock trades at a price-to-book of about 2.3 times. Return on capital employed is near zero at 0.96% and return on equity is negative at -9.36%, both reflecting the string of losses from Jun25 through Mar26. The dividend yield is minimal at 0.08%. Debt-to-equity stands at 1.16, a moderate level. Anyone following Indoco Remedies Q2 results should treat the four consecutive quarterly net losses as real reported losses and the Jun26 profit as a swing driven partly by a non-operating item rather than a clean like-for-like recovery. Indoco Remedies Q2 results for the September 2026 quarter will need to be read carefully in that light, and Indoco Remedies Q2 results overall highlight the gap between headline profit and core operating performance.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Indoco Remedies Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Indoco Remedies Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Indoco Remedies Ltd. reported revenue of Rs 468.00 crore in Q1 FY27, up 6.36% from Rs 440.00 crore in Q1 FY26, and a profit of Rs 65.00 crore at the net level, a swing from a loss of Rs 36.00 crore in Q1 FY26 to a profit of Rs 65.00 crore. These are reported actuals, not estimates.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/gabriel-india-q2-results-fy27-preview-date-expectations\">Gabriel India Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter<\/a><\/p>\n<p>Sequentially, revenue was down 1.68% over the March 2026 quarter figure of Rs 476.00 crore, and net profit was a swing from a loss of Rs 24.00 crore in Q4 FY26 to a profit of Rs 65.00 crore. Operating margin stood at 4.0% in Q1 FY27 against 9.0% in the September 2025 quarter, which is the comparison the Indoco Remedies Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Indoco_Remedies_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Indoco Remedies Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Indoco Remedies Ltd. reported revenue of Rs 485.00 crore and a loss of Rs 9.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Indoco Remedies Q2 results preview.<\/p>\n<p>Because the base quarter itself was loss-making, a year-on-year percentage comparison of profit is not meaningful for Indoco Remedies. The more useful test in the Indoco Remedies Q2 results print is whether the company reports a profit at all, and how the income line of Rs 485.00 crore compares with the Rs 468.00 crore of the June 2026 quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Indoco Remedies Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>485.00<\/td>\n<td>(9.00)<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>445.00<\/td>\n<td>(29.00)<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>476.00<\/td>\n<td>(24.00)<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>468.00<\/td>\n<td>65.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Indoco Remedies Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 445.00 crore to Rs 485.00 crore, and net profit from Rs 29.00 crore loss to Rs 65.00 crore. That spread is the honest context for the Indoco Remedies Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Indoco_Remedies_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Indoco Remedies Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Indoco Remedies Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Indoco Remedies has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Snapshot\"><\/span><strong>Valuation Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>P\/E and EPS are not meaningful for Indoco Remedies given the trailing loss position through most of the review period, so these ratios should not be read as valuation signals at present. Book value is Rs 102 per share, putting the price-to-book ratio at about 2.3 times the current price. Return on capital employed is near zero at 0.96% and return on equity is negative at -9.36%, both reflecting the string of losses reported from Jun25 through Mar26. The dividend yield is minimal at 0.08%. These figures point to a company still working through profitability challenges rather than one offering a clean valuation picture.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Technical_and_Price_Context\"><\/span><strong>Technical and Price Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Indoco Remedies shares have traded between a 52-week low of Rs 162.19 and a 52-week high of Rs 325, with the current price around Rs 238.1 positioned above the 50-day average of roughly Rs 229.32 but below the 200-day average of roughly Rs 251.03. The relative strength index reads 49.71, close to the midpoint of the typical range. This places the stock in a fairly neutral technical position relative to both its shorter and longer-term trend lines.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Payout\"><\/span><strong>Balance Sheet and Payout<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Indoco Remedies carries a debt-to-equity ratio of 1.16, a moderate level of borrowing on the balance sheet. The dividend yield is minimal at 0.08%, consistent with a company that reported net losses in four of the last five quarters and limited room for payouts. The Jun26 swing to a Rs 65 crore net profit, which exceeded that quarter&#8217;s Rs 41 crore operating profit, points to a non-operating item behind the result and should be treated as a data point to verify rather than a confirmed turnaround.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Indoco Remedies Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Indoco Remedies share price today is Rs 238.10 on the NSE, down Rs 3.29 or 1.36% from the previous close of Rs 241.39 on 16 September 2026, ahead of the Indoco Remedies Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (16 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>INDOCO<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 238.10<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 325.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 162.19<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 2198 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>Not meaningful on a trailing loss<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>2.33<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Not meaningful on a trailing loss<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 102.00<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>1.16<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>-9.36%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 229.32<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 251.03<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>49.71<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades above its 50-day average of Rs 229.32 but below its 200-day average of Rs 251.03, with a 14-day RSI of 49.71. None of this is a view on where the shares go once the Indoco Remedies Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Indoco Remedies Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Indoco_Remedies_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Indoco Remedies Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Indoco Remedies Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 485.00 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a loss of Rs 9.00 crore in that same quarter<\/li>\n<li>Operating margin against 4.0% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Indoco Remedies Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Indoco_Remedies_Q2_Results_FY27\"><\/span><strong>Conclusion on Indoco Remedies Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Indoco Remedies Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Indoco Remedies Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Indoco Remedies Q2 results FY27 print faces a base of Rs 485.00 crore in revenue and a loss of Rs 9.00 crore, with the most recent quarter having delivered Rs 468.00 crore and a profit of Rs 65.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Indoco Remedies, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Indoco_Remedies_Q2_Results_FY27\"><\/span><strong>FAQs on Indoco Remedies Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Indoco_Remedies_Q2_results_date_for_FY27\"><\/span><strong>What is the Indoco Remedies Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Indoco Remedies Q2 results date for FY27 is not confirmed. Indoco Remedies Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Indoco_Remedies_Q2_results_2026_cover\"><\/span><strong>What quarter do the Indoco Remedies Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Indoco Remedies Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Indoco Remedies Ltd. reports revenue, operating profit and net profit for that period, and the Indoco Remedies Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Indoco_Remedies_Q1_FY27_results\"><\/span><strong>What were the Indoco Remedies Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Indoco Remedies Ltd. reported revenue of Rs 468.00 crore in Q1 FY27 and a profit of Rs 65.00 crore at the net level. Revenue was up 6.36% versus Q1 FY26 and net profit was a swing from a loss of Rs 36.00 crore in Q1 FY26 to a profit of Rs 65.00 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Indoco_Remedies_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Indoco Remedies Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Indoco Remedies Ltd. reported revenue of Rs 485.00 crore and a loss of Rs 9.00 crore in Q2 FY26. Operating margin was 9.0%. Those figures form the base for the Indoco Remedies Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Indoco_Remedies_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Indoco Remedies Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Indoco Remedies Q2 results expectations centre on revenue against the Rs 485.00 crore base, net profit against a loss of Rs 9.00 crore, operating margin against 4.0% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Indoco_Remedies_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Indoco Remedies share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Indoco Remedies share price is Rs 238.10 on the NSE as of 16 September 2026, down 1.36% from Rs 241.39. The stock is about 26.7% below its 52-week high of Rs 325.00 and 46.8% above its 52-week low of Rs 162.19, at a market capitalisation of Rs 2198 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Indoco_Remedies_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Indoco Remedies a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Indoco Remedies Ltd. The stock trades at a price-to-book ratio of 2.33 with a return on equity of -9.36%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Indoco Remedies Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Indoco Remedies Q2 results date for FY27 is not confirmed. Indoco Remedies Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Indoco Remedies Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Indoco Remedies Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Indoco Remedies Ltd. reports revenue, operating profit and net profit for that period, and the Indoco Remedies Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Indoco Remedies Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Indoco Remedies Ltd. reported revenue of Rs 468.00 crore in Q1 FY27 and a profit of Rs 65.00 crore at the net level. Revenue was up 6.36% versus Q1 FY26 and net profit was a swing from a loss of Rs 36.00 crore in Q1 FY26 to a profit of Rs 65.00 crore.\"}},{\"@type\":\"Question\",\"name\":\"What were Indoco Remedies Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Indoco Remedies Ltd. reported revenue of Rs 485.00 crore and a loss of Rs 9.00 crore in Q2 FY26. Operating margin was 9.0%. Those figures form the base for the Indoco Remedies Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Indoco Remedies Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Indoco Remedies Q2 results expectations centre on revenue against the Rs 485.00 crore base, net profit against a loss of Rs 9.00 crore, operating margin against 4.0% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Indoco Remedies share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Indoco Remedies share price is Rs 238.10 on the NSE as of 16 September 2026, down 1.36% from Rs 241.39. The stock is about 26.7% below its 52-week high of Rs 325.00 and 46.8% above its 52-week low of Rs 162.19, at a market capitalisation of Rs 2198 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Indoco Remedies a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Indoco Remedies Ltd. The stock trades at a price-to-book ratio of 2.33 with a return on equity of -9.36%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Indoco Remedies Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Indoco Remedies Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":249107,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-249108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["249107"],"rank_math_title":["INDOCO Q2 FY27 Preview: Revenue, Loss &amp; Margin Trend"],"rank_math_description":["Indoco Remedies Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Indoco Remedies Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/indoco-remedies-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/249108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=249108"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/249108\/revisions"}],"predecessor-version":[{"id":249109,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/249108\/revisions\/249109"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/249107"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=249108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=249108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=249108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}